Prognostic factors for the clinical severity of keratoconjunctivitis sicca in patients with Sjögren's syndrome
- 1Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Republic of Korea
- 2Laboratory of Corneal Regenerative Medicine and Ocular Immunology, Seoul Artificial Eye Center, Seoul National University Hospital Clinical Research Institute, Seoul, Republic of Korea
- Correspondence to Professor Mee Kum Kim, Department of Ophthalmology, Seoul National University Hospital, 101 Daehang-ro, Jongno-gu, Seoul 110-744, Republic of Korea;
- Accepted 15 April 2011
- Published Online First 10 May 2011
Aims To determine whether prognostic immunological profiles predict the severity of keratoconjunctivitis sicca (KCS) in patients with Sjögren's syndrome (SS).
Methods 121 patients diagnosed with SS and followed for at least 1 year were enrolled in this study. Patients were allocated to either a mild KCS group (Mi-KCS; n=65) or to a moderate to severe KCS group (MS-KCS; n=56) based on the Oxford scheme and response to treatment. These groups were each sub-divided into two groups based on the clinical severity of KCS and the presence of associated rheumatic disease (primary SS vs secondary SS). Anti-Ro/anti-La antibody, rheumatoid factor and tear interleukin (IL)-17 levels and Schirmer test results were compared between each group.
Results Anti-Ro/SSA antibody and anti-La/SSB antibody concentrations were significantly higher in the MS-KCS group than in the Mi-KCS group for total and primary SS. The presence of anti-La/SSB antibody was significantly higher in the MS-KCS than the Mi-KCS group for total and primary SS. The mean tear IL-17 concentration in the MS-KCS group was significantly higher than in the Mi-KCS group for both total SS and primary SS patients.
Conclusion Serum anti-La/SSB antibody, serum anti-Ro/SSA antibody and tear IL-17 are likely to be strongly involved in the clinical severity of KCS in patients with primary SS.
- Anti-Ro/SSA antibody
- anti-La/SSB antibody
- keratoconjunctivitis sicca
- Sjögren's syndrome
- lacrimal gland
Funding This study was supported by Grant No. 0420090060 from the Seoul National University Hospital Research Fund.
Competing interests None declared.
Patient consent Obtained for tear collection of IL-17 study.
Ethics approval This study was conducted with the approval of the Seoul National University Hospital Institutional Review Board (H-1012-078-344 and H-0803-029-238).
Provenance and peer review Not commissioned; externally peer reviewed.